Q32 Bio Inc. and Homology Medicines, Inc., announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Tucson, AZ – September 19, 2023 – Ceria Therapeutics, Inc.(Ceria), an Arizona-based biotech startup focusing on the development of novel therapeutics to address several inflammatory diseases, today announced the company has received a third Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This award is directed to the development of CTX-002 for the treatment of progressive inflammatory lung disorders, including Acute Lung Injuries (ALI), Acute Lung Failure (ARF), and Acute Respiratory Distress Syndrome (ARDS).

WALTHAM, Mass. and DUBLIN, Sept. 13, 2023 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata. Q32 Bio and Horizon are collaborating to develop bempikibart, a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, two key immune pathways.

Tucson, AZ – October 3, 2023 – Ceria Therapeutics, Inc. (Ceria), an Arizona-based biotech startup focusing on the development of novel therapeutics to address several inflammatory diseases, today announced that the company has been awarded a contract from the United States Department of Defense’s (DoD) U.S. Army. This award is directed to the development of CTX-002 and a portable delivery device for the prevention and emergency treatment of acute lung injuries (ALI).

DENVER and SAN FRANCISCO, Aug. 16, 2023 /PRNewswire/ -- Core Biotherapeutics, a platform biotech company focused on creating the next generation of drugs to transform the lives of patients with cancer and other life-threatening diseases, has entered into a collaboration with the University of Colorado Anschutz Medical Campus (CU Anschutz) to expand the benefits of their therapeutic approach to Acute Myeloid Leukemia (AML) patients. This partnership was facilitated by CU Innovations, the CU Anschutz department tasked with bringing together industry partners, entrepreneurs, investors, and CU Anschutz researchers to translate technology to improve outcomes for patients worldwide.

DENVER, CO / ACCESSWIRE / July 17, 2023 / Laxxon Medical, a leading 3D screen printing pharma-technology company, announced today their strategic partnership with CU Innovations at the University of Colorado Anschutz Medical Campus (CU Anschutz). The partnership will create an opportunity for researchers at CU Anschutz to develop novel drug therapies using Laxxon's 3D screen printing technology, SPID®-Technology (Screen Printing Innovational Drug Technology).

The SPARK | REACH Program is the go-to program on campus for anyone who has promising proof-of-concept data in the lab. SPARK helps develop technologies that address unmet medical needs and will open for new applications on June 19.

The event was sponsored by CU Innovations, the university’s bridge between cutting-edge technologies developed on campus and industry partners, entrepreneurs and investors. It was held in the Donald M. Elliman Conference Center in the Anschutz Health Sciences Building.